Regulus Therapeutics
RGLS
#7290
Rank
โ‚น54.36 B
Marketcap
โ‚น785.20
Share price
0.00%
Change (1 day)
498.29%
Change (1 year)

Earnings for Regulus Therapeutics (RGLS)

Earnings in 2025 (TTM): -โ‚น4.02 Billion

According to Regulus Therapeutics's latest financial reports the company's current earnings are N/A. In 2024 the company made an earning of -โ‚น4.45 Billion a decrease over its 2023 earnings that were of -โ‚น2.84 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Regulus Therapeutics from 2012 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) -โ‚น4.02 Billion-9.76%
2024 -โ‚น4.45 Billion56.97%
2023 -โ‚น2.84 Billion6.51%
2022 -โ‚น2.66 Billion2.53%
2021 -โ‚น2.6 Billion93.59%
2020 -โ‚น1.34 Billion-15.41%
2019 -โ‚น1.59 Billion-64.46%
2018 -โ‚น4.46 Billion-33.26%
2017 -โ‚น6.68 Billion-13.98%
2016 -โ‚น7.77 Billion44.77%
2015 -โ‚น5.37 Billion-1.63%
2014 -โ‚น5.46 Billion203.6%
2013 -โ‚น1.8 Billion8.65%
2012 -โ‚น1.66 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Sanofi
SNY
โ‚น736.93 B-16,247.25%๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
โ‚น156.17 B-3,521.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚น923.47 B-20,334.46%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
โ‚น1.411 T-31,017.79%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
โ‚น963.34 B-21,208.18%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sangamo Therapeutics
SGMO
-โ‚น10.62 Billion 132.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
-โ‚น11.33 Billion 148.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
โ‚น83.68 B-1,933.62%๐Ÿ‡บ๐Ÿ‡ธ USA